NEWRegulation

Galderma (GLDM) Faces FDA Setback for Botox Rival Drug

Published on 7/1/2026

#GLDM#FDA#Botox#stock decline#aesthetics
Galderma (GLDM) Faces FDA Setback for Botox Rival Drug

AI Summary

Galderma's stock dropped following the FDA's second setback regarding its rival to Botox. The company has been working on a new injectable treatment aiming to compete in the aesthetics market. The setbacks from the FDA could delay the product launch, impacting anticipated revenue streams. This event raises concerns about regulatory hurdles and market positioning for Galderma (GLDM).

Source: Read original article (opens in new tab)

Related News

Australia Considers Break-Up of Big Four Accounting Firms
Regulation

Australia Considers Break-Up of Big Four Accounting Firms

Jul 1

EU Imposes €3 Fee on Ecommerce Parcels Impacting Shein (SHEIN)
Regulation

EU Imposes €3 Fee on Ecommerce Parcels Impacting Shein (SHEIN)

Jul 1

Google (GOOGL) Allegations by South Korea's Trade Watchdog Overview
Regulation

Google (GOOGL) Allegations by South Korea's Trade Watchdog Overview

Jul 1

FDA Questions Kennedy-Backed Peptides Ahead of Advisory Panel Review
Regulation

FDA Questions Kennedy-Backed Peptides Ahead of Advisory Panel Review

Jun 30